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Abstract
Pokeweed antiviral protein (PAP) is a plant-derived N-glycosidase that exhibits antiviral activity against several viruses. The
enzyme removes purine bases from the messenger RNAs of the retroviruses Human immunodeficiency virus-1 and Human
T-cell leukemia virus-1. This depurination reduces viral protein synthesis by stalling elongating ribosomes at nucleotides
with a missing base. Here, we transiently expressed PAP in cells with a proviral clone of HIV-1 to examine the effect of the
protein on virus production and quality. PAP reduced virus production by approximately 450-fold, as measured by p24
ELISA of media containing virions, which correlated with a substantial decline in virus protein synthesis in cells. However,
particles released from PAP-expressing cells were approximately 7-fold more infectious, as determined by single-cycle
infection of 1G5 cells and productive infection of MT2 cells. This increase in infectivity was not likely due to changes in the
processing of HIV-1 polyproteins, RNA packaging efficiency or maturation of virus. Rather, expression of PAP activated the
ERK1/2 MAPK pathway to a limited extent, resulting in increased phosphorylation of viral p17 matrix protein. The increase in
infectivity of HIV-1 particles produced from PAP-expressing cells was compensated by the reduction in virus number; that is,
virus production decreased upon de novo infection of cells over time. However, our findings emphasize the importance of
investigating the influence of heterologous protein expression upon host cells when assessing their potential for antiviral
applications.
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Introduction
Pokeweed antiviral protein (PAP) is a type I ribosome
inactivating protein isolated from the pokeweed plant, Phytolacca
americana [1]. Like all ribosome inactivating proteins, PAP is an N-
glycosidase that removes a specific adenine base from the
conserved sarcin/ricin loop of the large ribosomal RNA [2].
Depurination of rRNA slows the elongation step of translation by
inhibiting the binding of elongation factor 2 (EF-2) [3,4]. Resulting
cytotoxicity has been cited to explain the antiviral properties of
some of these enzymes [5]; namely, host cell death would hinder
virus proliferation. However, subsequent studies have shown that
antiviral activity can be achieved in the absence of cell death.
Specifically, treatment of HIV-1 infected T-lymphocytes with
purified PAP reduced virus production without causing cytotox-
icity [6]. Moreover, PAP depurinates Human immunodeficiency
virus-1 (HIV-1) genomic RNA in vitro [7] and we have shown
recently that depurination of Human T-cell leukemia virus-1
(HTLV-1) gag mRNA decreased its translational efficiency
without reducing cellular translation rates [8]. These findings
suggest that the substrate specificity of PAP is not limited to rRNA
and that antiviral activity is due to depurination of viral RNAs and
resulting inhibition of viral protein synthesis. Although PAP
substantially reduces HIV-1 production from infected cells, its
application as an anti-HIV-1 agent requires a clear understanding
of its effects on other virus life-cycle events, such as infection of
target cells, which reflects the quality of virus particles produced
from cells exposed to PAP.
A number of HIV-1 particle characteristics are known to
influence the infectivity of this virus. For example, the relative
amounts of processed HIV-1 structural and enzymatic proteins,
such as envelope glycoprotein (Env) [9], Gag [10] and reverse
transcriptase (RT) [11] affect the degree of maturation, and
thereby infectivity, of HIV-1 particles. The efficiency of genomic
RNA packaging within virus particles is another factor known to
significantly enhance virus infectivity by increasing the number of
replication competent HIV-1 particles [12]. Several cellular
proteins have also been reported within HIV-1 particles [13].
Although the precise roles of most of these in the HIV-1 life-cycle
are not well understood, some have been found to affect virus
infectivity. Specifically, HIV-1 packages serine-threonine kinases
such as ERK2 MAPK [14,15] and cellular protein kinase A (C-
PKA) [16] upon budding from cells, and activation of these kinases
by cytokines and mitogens inside virus-producing cells caused
release of more infectious particles [15,16]. ERK2 MAPK
predominantly phosphorylates matrix (MA) protein [15], while
C-PKA was shown to phosphorylate capsid (CA) protein in vitro
[16]. MA phosphorylation increased the nuclear localization of
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required for complete reverse transcription, given that mutants of
CA unable to undergo phosphorylation were impaired for reverse
transcription [18]. Therefore, current data suggest that the
incorporation of some activated cellular kinases in particles is
required for optimal infectivity.
In this study, we investigated the effects of PAP expression on
HIV-1 production and infectivity. To determine whether PAP
affects the quality of particles, we assessed the maturation of virion
proteins and tested the efficiency of genomic RNA packaging
within particles, and conclude that neither is altered by PAP.
Surprisingly, PAP enhanced the infectivity of particles, which we
attribute to activation of ERK2 kinase in virus particles, as shown
by increased phosphorylation of MA protein during an in vitro
kinase assay. Though we predict that this increase will be
compensated by the more substantial decrease in particle
production, we provide new information on the influence of
PAP expression in cells that is relevant to understanding its
effectiveness as a potential antiviral agent.
Results and Discussion
PAP reduces HIV-1 production from cells
We examined the effect of PAP on HIV-1 production by
transient transfection of 293 T cells with the proviral clones
pMenv(-) or pNL4-3, and 3x-Flag-PAP, 3x-Flag-PAPx or vector
control (pcDNA3). PAPx is the enzymatically inactive mutant of
PAP that serves as a negative control for PAP activity [19], and
immunoblot analysis using a Flag-specific antibody indicated that
both PAP and PAPx were expressed in cells (Figure 1A). To assess
virus production, media of cells were collected 40 hours following
transfection and a p24 CA ELISA was performed. Increasing
amounts of PAP plasmid transfected into cells with pMenv(-)
reduced the amount of HIV-1 particles in a dose-dependent
manner (Figure 1B). p24 CA protein level was extremely low at the
highest amount of 3x-Flag-PAP plasmid (1 mg) transfected into
cells, such that we used a log scale to illustrate these values.
Expression of PAPx did not alter virus production levels relative to
vector control (pcDNA3), suggesting that the enzymatic activity of
PAP was responsible for inhibition of virus production. The
ELISA results were confirmed by immunoblot analysis of virus
particles pelleted by ultracentrifugation from equal volumes of
media, showing that PAP reduced Gag protein products to
undetectable levels (Figure 1C).
Decrease in virus production was not due to loss of viability of
cells expressing PAP. MTT assay results agreed with our previous
observations that PAP is not toxic to 293 T cells (Figure 2A; 8). To
determine whether reduction in virus production was due to
defects in virus assembly or release from cells, the efficiency of
virus release was tested by comparing the amount of p24 CA
protein in the media to Gag protein synthesized in cells. The
amounts of Gag protein products, including p55, p41 and p24,
inside cells were assessed by immunoblot (Figure 2B) and ELISA
(not shown) using a p24-specific antibody. Consistent with
reduction of virus particles released into the media, PAP reduced
expression of Gag protein products to barely observable levels
inside cells. Therefore, reduction in virus production from cells
expressing PAP was likely due to lower expression of Gag protein
inside cells, rather than defects in virus assembly or release. The
expression of the reverse transcriptase (RT), Nef and Env (gp120)
proteins was also decreased in lysates of cells expressing PAP,
suggesting that PAP inhibits the expression of both structural and
regulatory viral proteins. These data are consistent with a previous
study showing that incubation of HIV-1 infected T cells with PAP
immunoconjugates reduced the levels of viral proteins in the cells
(6); however, the resulting particle characteristics were not
assessed.
Figure 1. PAP reduces HIV-1 production from cells. (A)
Immunoblot analysis of PAP expression in 293 T cells transfected with
3x-Flag-PAP (0.5, 1.0 or 2.5 mg), 3x-Flag-PAPx (0.5 mg) or pcDNA3
(2.5 mg) plasmids. Total cellular protein (100 mg) was resolved on a 12%
SDS-PAGE, transferred to nitrocellulose and probed with Flag mono-
clonal antibody (1:1,000) and b-actin monoclonal antibody (1:5,000). (B)
293 T cells were transfected with pMenv(-) proviral clone (5 mg) and 3x-
Flag-PAP (0.12, 0.25, 0.5 or 1.0 mg), 3x-Flag-PAPx (1.0 mg) or pcDNA3
(1.0 mg). Media of cells were collected 40 hours following transfection
and virus production was estimated using a p24 CA ELISA. Values are
plotted on log scale and are means 6 S.E. from triplicate samples of
three different experiments. (C) Equal volume of media (1 mL) was
centrifuged and pelleted virus particles were separated through 12%
SDS-PAGE followed by immunoblotting using a p24 CA-specific
monoclonal antibody (1:5,000). The blot is representative of three
separate experiments.
doi:10.1371/journal.pone.0036369.g001
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As a measure of virus quality, we tested the infectivity of
particles released from PAP-expressing cells. Particles were
purified from media of 293 T cells co-expressing the proviral
clone pNL4-3, and 3x-Flag-PAP, 3x-Flag-PAPx or vector control
(pcDNA3). A low amount of PAP (0.5 mg) was transfected into
cells to allow sufficient virus production for further analysis. Virus
infectivity was assessed by single-cycle infection of the 1G5
reporter cell line with equivalent amounts of particles. The extent
of HIV-1 LTR activation was determined by luciferase activity in
the lysate of 1G5 cells harvested 48 hours following infection to
measure the extent of HIV-1 particle infectivity. Cells were treated
with AZT 8 hours following infection to prevent further rounds of
infection. Co-expression of PAP and HIV-1 in cells resulted in
approximately 7-fold increased infectivity of virus progeny relative
to those from cells expressing PAPx or pcDNA3 (Figure 3A).
To confirm the effect of PAP on virus infectivity, we performed
productive infection analysis using the human T-lymphoblastoid
cell line (MT2). The cells were infected with normalized p24 CA
amounts of virus, and replication was monitored by removing
aliquots of cell media over a 21-day period and testing for virus
Figure 2. PAP decreases expression of HIV-1 proteins without
toxicity to cells. 293 T cells were transfected with the pNL4-3 proviral
clone (5 mg) and 2 mg 3x-Flag-PAP, 3x-Flag-PAPx or pcDNA3 vectors.
Cells were harvested 40 hours following transfection. (A) Viability was
tested by an MTT conversion assay. Values are percentages relative to
pcDNA3, as means 6 S.E. for three independent experiments. (B) Total
cellular protein (150 mg) was separated through 10% SDS-PAGE,
followed by immunoblot analysis using p24 CA-specific monoclonal
antibody (1:5,000), or polyclonal antibodies specific for Nef (1:2,000), RT
(1:2,500) or gp120 (1:5,000). Samples were probed with b-actin
monoclonal antibody (1:5,000) to control for equal protein loading in
each lane. The blots are representative of three separate experiments.
doi:10.1371/journal.pone.0036369.g002
Figure 3. PAP increases HIV-1 particle infectivity. Virus particles
were generated by transfection of 293 T cells with the pNL4-3 proviral
clone (5 mg) and 0.5 mg 3x-Flag-PAP, 3x-Flag-PAPx or pcDNA3 vectors.
(A) Equivalent amounts of purified virus (12 ng) in 1 mL of media were
used for a single-cycle infection of 1610
5 1G5 cells in a 24-well plate.
The cells were washed 8 hours following infection and treated with AZT
(10 mM). Following another 40 hours of incubation, the cells were
harvested, lysed and a luciferase assay was performed to determine
relative virus infectivity. Values are means 6 S.E. from triplicate samples
of three different experiments. (B) Equivalent amounts of purified virus
(16 ng) in 1 mL of media were used to infect 1610
5 MT-2 cells in a 24-
well plate. Following 4 hours of incubation, the cells were washed with
medium and incubated for another 21 days. Aliquots of media were
collected on daily intervals and virus production was determined by
p24 CA ELISA. Values are means 6 S.E. from triplicate samples of three
different experiments. Virus particles used for infection and produced
from cells expressing PAP or vector control are indicated by circles or
squares, respectively.
doi:10.1371/journal.pone.0036369.g003
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infectivity assays, prior co-expression of PAP with HIV-1 resulted
in production of more infectious virus particles (Figure 3B). To
determine whether changes in virus infectivity were due to factors
released from PAP-expressing cells or a specific feature of virus
particles produced from these cells, we also tested the effect of
media from cells expressing only PAP on infectivity of purified
virus particles produced from cells co-transfected with pcDNA3
and pNL4-3,. This was done by mixing filtered media collected
from cells expressing PAP alone with purified virus particles from
cells co-transfected with pcDNA3 and pNL4-3. We did not detect
any changes in virus infectivity with this treatment (data not
shown), suggesting that expression of PAP in virus producing cells
may have altered specific components of HIV-1 particles.
Increased virus infectivity is not due to changes in gag/
pol protein levels in HIV-1 particles
To determine the effect of PAP on HIV-1 particle composition,
we analyzed the relative amounts of virion-associated reverse
transcriptase (RT), envelope glycoprotein (Env) and Gag poly-
protein. Proteins from equivalent amounts of highly purified virus
particles from media of 293 T cells expressing pNL4-3 and 3x-
Flag-PAP, 3x-Flag-PAPx or pcDNA3 were visualized by sequen-
tial immunoblot analysis using rabbit anti-RT, sheep anti-gp120
and mouse anti-p24 CA antibodies. No notable differences were
detected in the relative amounts of RT, Env and Gag proteins in
virions from PAP-expressing cells, suggesting that changes in virus
infectivity were not due to alteration in the levels of these proteins
in virus particles (Figure 4A). In addition, similar ratios of RT
heterodimer (p51
pol and p66
pol), gp120
env, intermediate processing
product of Gag (p41
gag) and fully processed Gag (p24 CA
gag) were
detectable in virus particles purified from cells expressing PAP,
PAPx or pcDNA3 (Figure 4A), suggesting that changes in virus
infectivity were not likely due to alteration in the processing of
viral proteins and degree of virus maturation.
HIV-1 RNA packaging efficiency is not affected by PAP
Increased efficiency of genomic (gag/pol) RNA packaging into
virus particles has been shown to enhance HIV-1 infectivity [12],
since not all virus particles package the full-length RNA. To test
whether expression of PAP caused an increase in genomic mRNA
packaging into HIV-1 particles, total RNA was isolated from
normalized amount of p24 CA virus particles that were purified
from media of 293 T cells co-expressing the proviral clone pNL4-3
and 3x-Flag-PAP, 3x-Flag-PAPx or vector control. RNase pro-
tection assay on isolated virion RNA indicated no obvious changes
in the relative efficiency of viral RNA packaging into virus
particles (Figure 4B), suggesting that increased virus infectivity was
not likely due to enhanced genomic RNA packaging. To control
for equal pelleting of virus particles, immunoblot analysis was
performed on a fraction of each sample using a p24 CA-specific
antibody (Figure 4B, lower panel).
PAP increases p17 matrix protein phosphorylation
A number of viruses, including HIV-1, incorporate cellular
signaling molecules, referred to as virus-associated protein kinases
(VAPKs), within their particles [20]. VAPKs, such as ERK2
MAPK, have been shown to play a role in HIV-1 infectivity by
phosphorylating p17 MA protein [15], which facilitates the
nuclear import of HIV-1 preintegration complexes [17]. Since
the main substrate for ERK2 within HIV-1 particles is the p17
MA protein, the effect of PAP expression on the activation of
ERK2 was assessed by co-transfecting the proviral clone pMenv(-)
with 3x-Flag-PAP, 3x-Flag-PAPx or vector control and testing the
extent of MA phosphorylation inside virus particles by an in vitro
kinase assay. Equivalent amounts of purified virus from media
were used for this kinase assay, and as shown in Figure 5, increase
of a phospho-protein was visible in HIV-1 particles produced from
PAP-expressing cells, but not from cells transfected with PAPx or
vector control. As an experimental control, supernatant of PAP-
expressing cells without the virus was also ultracentrifuged and
tested in the kinase assay. However, no radiolabeled proteins were
detected in this sample, suggesting that the observed band was
virus-specific, corresponding to the molecular weight of phosphor-
ylated MA protein.
Figure 4. PAP does not alter HIV-1 virus particle composition.
Virus particles were collected from media of 293 T cells transfected with
the pNL4-3 proviral clone (5 mg) and 0.5 mg 3x-Flag-PAP, 3x-Flag-PAPx
or pcDNA3 vectors. (A) Particles were purified by ultracentrifugation
through a 20% sucrose cushion and equivalent amounts of purified
virus (100 ng) were resolved on 10% SDS-PAGE. Viral proteins were
then transferred to nitrocellulose and probed with antibodies specific
for RT (1:2,500), gp120 (1:5,000) and p24 CA (1:5,000) proteins. (B) RNA
was isolated from equivalent amounts of purified virus particles
(100 ng) and analyzed by RNase protection assay using an antisense
riboprobe complementary to the gag ORF (nt 600–820). A fraction of
the purified viruses was used for immunoblot analysis of p24 CA to
control for equal virus pelleting from each sample (lower panel). Blots
are representative of five independent experiments performed in
triplicate.
doi:10.1371/journal.pone.0036369.g004
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inside virus particles produced from cells expressing PAP was likely
due to higher levels of active ERK2 inside particles, the extent of
virion protein phosphorylation was analyzed by treatment of cells
co-expressing the proviral clone pMenv(-) and 3x-Flag-PAP with
PD98059 [2-(29-amino-39-methoxyphenyl)oxanaphthalen-4-one].
PD98059 is a specific inhibitor of MAPK activating enzyme,
MAPK kinase (MEK) [21], which prevents activation of MAPK
and subsequent phosphorylation of MAPK substrates [22].
Incorporation of c
33P-ATP into virion-associated p17 MA was
reduced upon treatment of cells with PD98059, suggesting that
increased p17 MA phosphorylation was due to higher levels of
active ERK2 inside purified HIV-1 particles produced from cells
expressing PAP (Figure 5, upper panel). Consistent with previous
reports, PD98059 did not significantly lower virus production from
cells as tested by ELISA (data not shown). As an experimental
control, viruses were purified from media of 293 T cells co-
transfected with HIV-1 proviral clone and a plasmid encoding
constitutively active MEK (MEKAC). As expected, viruses pro-
duced from these cells showed a higher degree of p17 MA
phosphorylation compared to cells co-transfected with pcDNA3
(Figure 5, upper panel). A portion of the pelleted virions was used
for immunoblot analysis using anti-p17 MA antibody to ensure
similar amounts of virus particles in the kinase assay samples
(Figure 5, lower panel). These results suggest that expression of
PAP inside cells increased the activity of ERK2 within HIV-1
particles. Our attempts at immunoblot analysis of phospho-ERK2
inside virus particles were unsuccessful, because the amount of
virus produced from PAP-expressing cells was too low to allow
detection.
PAP increases the level of active MEK and ERK1/2 inside
cells
Activation of the cellular ERK1/2 MAPK signaling pathway by
extracellular stimuli has been shown to increase the level of
phosphorylated ERK2 packaged inside HIV-1 particles [15],
which in turn, enhanced virus infectivity. To determine whether
PAP activated MEK and ERK1/2 in cells, we transfected 293 T
cells with 3x-Flag-PAP and compared the level of phosphorylated
MEK and ERK1/2 to cells transfected with 3x-Flag-PAPx,
pcDNA3 or MEKAC (encoding constitutively active MEK).
Expression of PAP increased the level of phospho-MEK by a small
degree relative to cells transfected with PAPx or pcDNA3
(Figure 6A). As expected, activation of MEK was substantially
less than that observed for cells expressing the constitutively active
form of the protein (MEKAC). The level of total MEK remained
unchanged in PAP-expressing cells, indicating that PAP enhanced
the activity of MEK, rather than increasing MEK synthesis. To
determine whether this minor degree of MEK activation affected
its downstream target ERK1/2, we also tested activation of
ERK1/2 in the presence of PAP. Expression of PAP increased the
level of active phosphorylated ERK1/2 in a concentration
dependent manner, while the total amount of ERK1/2 inside
the cells remained unaffected (Figure 6A). The double bands seen
in all the lanes represented the two isoforms ERK1 (44 kDa) and
ERK2 (42 kDa). Maximum ERK1/2 phosphorylation was
detected in the positive control lane (MEKAC). Although the
increase in ERK1/2 phosphorylation was moderate relative to
constitutively active MEK, it appeared consistently in several
replicate assays and was effectively reduced by the MEK specific
inhibitor PD98059.
To confirm that ERK1/2 was more active in cells expressing
PAP, an in vitro kinase assay was performed on lysates of 293 T
cells expressing 3x-Flag-PAP, 3x-Flag-PAPx, pcDNA3 or MEKAC.
Total cellular ERK1/2 was immunoprecipitated from cell lysates
using antibodies specific for ERK1/2, followed by addition of
myelin basic protein (MBP) as substrate for ERK1/2 and c
33P-
ATP as phosphate donor. As indicated in Figure 6B (upper panel),
lysate of cells expressing PAP showed a higher degree of MBP
phosphorylation than cells expressing PAPx or pcDNA3, although
similar amounts of ERK1/2 precipitated from each sample
(Figure 6B, lower panel). Greater phosphorylation of MBP was
achieved in immunoprecipitated lysate of cells expressing consti-
tutive MEK (MEKAC), which was consistent with the result from
immunoblot analysis of phospho-ERK1/2 levels. Furthermore,
treatment with PD98059 of cells transfected with MEKAC or 3x-
Flag-PAP reduced the level of MBP phosphorylation, suggesting
that phosphorylation was due to active ERK1/2 immunoprecipi-
tated from lysates of cells (Figure 6B). The immunoblot analysis
and kinase assay indicated that PAP activated ERK1/2 MAPK,
and activation of this kinase may be responsible for increased virus
infectivity.
It is uncertain how PAP may be activating ERK1/2, but
previous studies have shown that several ribosome inactivating
proteins cause the phosphorylation of kinases involved in the
MAPK pathway, most often resulting in cell death [23–25].
Cytotoxicity, in turn, has been used to explain antiviral activity,
as host cell death would diminish virus proliferation. For
example, the antiviral activity of trichosanthin, a ribosome
inactivating protein, is attributed to its ability to reduce levels of
the anti-apoptotic protein Bcl-2 [26], thought to be controlled at
the transcriptional level by members of the MAPK pathway
upstream of cAMP response element binding protein (CREB)
[27]. These findings agree with earlier work showing that
trichosanthin induces apoptosis in HIV-1 infected cells [28]. In
Figure 5. PAP increases the phosphorylation of p17 matrix
protein. 293 T cells were transfected with the pMenv(-) proviral clone
(5 mg) and 0.5 mg 3x-Flag-PAP, 3x-Flag-PAPx, pcDNA3 or MEKAC vectors.
Cells co-transfected with PAP and HIV-1 and cells transfected with HIV-1
alone were additionally treated with 20 mM of the MEK inhibitor
PD98059. Particles were purified by ultracentrifugation through a 20%
sucrose cushion and equivalent amounts of purified virus (30 ng) were
pelleted, lysed and subjected to an endogenous kinase assay using
[c33P-ATP] as a phosphate donor. Samples were resolved on 15% SDS-
PAGE and phosphorylated p17 was visualized using a phosphorimager.
Fractions of pelleted virus were analyzed via immunoblot using a p17-
MA-specific antibody (1:1,000). Blots are representative of four separate
experiments.
doi:10.1371/journal.pone.0036369.g005
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sion in cultured cells does not cause cellular changes character-
istic of programmed cell death, such as cleavage of caspase-3 and
PARP and increased cell permeability [29]. We have shown
previously that PAP activates the JNK/SAPK pathway but not
p38/HOG MAPK signaling pathways in 293 T cells [29]. The
activation is triggered by depurination of the 28S rRNA, which
mediates a signal that is transduced by the JNK/SAPK pathway
[30]. However, PAP does not decrease cell viability or cellular
translation rate, likely because a small percentage (16%) of
ribosomal RNA is depurinated [8].
Activation of ERK2 by PAP contributes to increased virus
infectivity
To test that modulation of ERK2 activity inside virus particles
produced from cells expressing PAP altered virus infectivity, cells
co-expressing PAP and HIV-1 (pNL4-3) were treated with MEK
inhibitor (PD98059) 18 hours following transfection. Equivalent
amounts of purified virus particles collected from these cells were
then used to infect the 1G5 reporter cell line. Cells were treated
with AZT 8 hours following infection to ensure that only a single
round of infection occurred while cells were incubated for an
additional 40 hours. Analysis of luciferase activity in lysates of
these cells indicated that while expression of PAP caused an
increase in virus infectivity, treatment of PAP-expressing cells
with PD98059 reduced virus infectivity to levels similar to virus
particles produced from cells transfected with pcDNA3 (Figure 7).
As expected, PD treatment of cells not expressing PAP did not
alter infectivity of released virions. These data suggest that
activation of ERK2 contributed to increased infectivity of virus
particles generated from PAP-expressing cells.
PAP reduces productive HIV-1 infection
Results from our study show that although co-expression of PAP
with HIV-1 substantially lowered the production of virus, these
particles were more infectious, likely due to increased ERK1/2
Figure 6. PAP activates ERK1/2 MAPK in cells. (A) 293 T cells were
transfected with 3x-Flag-PAP (0.5, 1.0, or 2.5 mg), 3x-Flag-PAPx (2.5 mg),
pcDNA3 (2.5 mg) or MEKAC (1.0 mg) vectors. 24 hours prior to trans-
fection, cells were refed with DMEM without FBS until they were
harvested. A portion of cells transfected with 3x-Flag-PAP (2.5 mg) was
treated with the MEK inhibitor PD98059 (20 mM). Total cellular protein
(100 mg) was resolved through 12% SDS-PAGE, followed by sequential
immunoblot analysis using antibodies specific for phospho-MEK
(1:2,000), MEK (1:2,000), phospho-ERK1/2 (1:2,000), ERK1/2 (1:2,000)
and b-actin (1:5,000). (B) Total ERK1/2 was immunoprecipitated from
lysate of cells (300 mg total protein), followed by a kinase assay using
MBP as substrate. Cells transfected with 3x-Flag-PAP (1.0 mg) or MEKAC
(1.0 mg) were also treated with 20 mM PD98059 MEK inhibitor.
Phosphorylated proteins were visualized with a phosphorimager. A
fraction of immunoprecipitated proteins was analyzed by immunoblot-
ting using an ERK1/2 specific antibody (1:5,000). Blots are representative
of four independent experiments.
doi:10.1371/journal.pone.0036369.g006
Figure 7. Infectivity of HIV-1 particles decreases upon treat-
ment with MEK inhibitor. 293 T cells were transfected with 5 mg
pNL4-3 and 0.5 mg 3x-Flag-PAP or pcDNA3 plasmids. Cells transfected
with 3x-Flag-PAP plasmid or untransfected were also treated with
PD98059 (20 mM). Virus particles were purified from the media of cells
collected 40 hours following transfection and equivalent amounts of
virus particles (3 ng) were used to infect 1610
5 1G5 cells. Cells were
washed and re-fed with fresh medium containing AZT (10 mM) 8 hours
following infection and incubated for an additional 40 hours. Cells were
harvested, lysed and a luciferase assay was performed to determine
relative virus infectivity. Values are means 6 S.E. from triplicate samples
of three different experiments.
doi:10.1371/journal.pone.0036369.g007
PAP Increases HIV-1 Infectivity
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PAP on virus production and infectivity would result in greater
virus production upon de novo infection of cells over time. For this
assay, equal volumes of media from cells expressing pNL4-3 with
PAP or pcDNA3 were used to infect MT-2 cells and virus
production from these cells was assessed over a 21-day period
using a p24 CA ELISA (Figure 8). MT2 cells infected with
medium from PAP-expressing cells produced significantly less
virus over this time compared with medium from vector control
cells. Therefore, although PAP enhanced virus infectivity, this
effect was compensated by the low amount of virus released from
PAP-expressing cells.
When evaluating the potential of PAP as an antiviral agent, it
is important to assess its effects on the host cell in addition to the
virus. We acknowledge that our experiments were conducted
entirely in cell lines and that they would need to be confirmed in
primary cells; however, the transfection of 0.5 mg of PAP DNA
into 293 T cells caused a 7-fold increase in particle infectivity, as
measured by a single-cycle infection. This same amount of
transfected PAP DNA increased phosphorylation levels of MEK
and ERK1/2 to a minor extent above those of negative control
cells, indicating that even modest modulation of cellular proteins
can have substantial effect on stages of the virus life cycle. In
addition to increasing virus infectivity, PAP significantly de-
creased particle production. Namely, transfection of the same
amount of PAP DNA, which represented a level of protein just
visible by immunoblotting, reduced virus particle production by
approximately 450-fold. Therefore, increased infectivity may not
contribute significantly to the progress of infection if virus levels
are barely detectable by ELISA. Even though PAP is not
expressed to a high degree in 293 T cells, it substantially
suppresses HIV-1 production, suggesting that the protein has
potential as an effective inhibitor of HIV-1 replication at low
concentrations.
Materials and Methods
Cell lines
293 T cells (ATCC, catalog # CRL-11268) were maintained in
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented
with 10% heat-inactivated fetal bovine serum (FBS), penicillin
(100 U/mL) and streptomycin (100 mg/mL). 293 T cells used to
determine MEK and ERK1/2 levels and activity were maintained
in the same manner as described above until 24 hours prior to
transfection. At this time, the cells were grown in DMEM without
FBS until they were harvested. The HIV-1 indicator cell line 1G5
(NIH AIDS Reference and Reagent Program, catalog # 1819) is
a derivative of Jurkat cells stably transfected with a reporter
construct containing the HIV-1 long terminal repeat (LTR)
upstream of the luciferase gene [31]. These cells were maintained
in RPMI 1640 medium, supplemented with 10% FBS, penicillin
(100 U/mL) and streptomycin (100 mg/mL). Human lympho-
blastoid T-cell line MT-2 (NIH AIDS Reference and Reagent
Program, catalog # 237) was maintained in RPMI 1640,
supplemented with 10% FBS, penicillin (100 U/mL) and
streptomycin (100 mg/mL). All cells were cultured at 37uC with
5% CO2.
Plasmid constructs and antibodies
Plasmids 3x-Flag-PAP and 3x-Flag-PAPx were described
previously [29]. The proviral clones pMenv(-) (catalog # 2089)
and pNL4-3 (catalog # 114) were obtained from NIH AIDS
Reference and Reagent Program. The plasmid pMenv(-) has
been described previously [32] and results in production of non-
infectious HIV-1 particles. The plasmid encoding constitutively
active MEK (MEKAC; DN3 S218D/S222E; [33]) was generously
provided by Dr. J. C. McDermott (York University, Canada).
Polyclonal antibodies specific for MEK (catalog # 9122),
phospho-MEK (catalog # 9154), ERK1/2 (catalog # 9102) and
phospho-ERK1/2 (catalog # 4377) were purchased from Cell
Signaling. Mouse anti-p24 CA (catalog # 6457), rabbit anti-RT
(catalog # 6195), anti-Nef (catalog # 2949), anti-p17 MA
(catalog# 4811) and sheep anti-gp120 (catalog # 288) were
obtained from NIH AIDS Reference and Reagent Program.
Mouse M2 anti-Flag antibody (catalog # F3165) was purchased
from Sigma Aldrich.
Transfection, MTT assay, and generation of virus stocks
293 T cells were transiently transfected using the calcium
chloride transfection method, as described previously [29]. Briefly,
5610
6 cells in 10-cm plates were transfected with 5 mg proviral
DNA (pNL4-3 or pMenv(-)) and the indicated amounts of 3x-Flag-
PAP, 3x-Flag-PAPx, pcDNA3 or pMEKAC. Cellular viability was
judged using an MTT conversion assay (Roche Applied Science)
as per the manufacturer’s instructions. Approximately 40 hours
after transfection, cells were seeded into a 96- well plate and MTT
reagent (20 mL) was added to each well. The plate was incubated
at 37uC for 4 hours after which 100 mL of Solubilizing buffer was
added to each well and the plate was incubated at 37uC for an
additional for 4 hours. Following incubation, absorbance was
measured at 595 nm.
The media of cells were collected or cells were harvested
48 hours following transfection for virus purification or protein
expression analysis, respectively. Media collected from cells were
clarified by centrifugation at 3,0006 g for 10 minutes, filtered
through a 0.22 mM filter, and then pelleted through a 20%
sucrose cushion by ultracentrifugation at 184,0006 g for
90 minutes at 4uC. Pelleted virus particles were resuspended in
buffers appropriate for subsequent experiments or aliquoted and
Figure 8. Decreased synthesis of HIV-1 particles by PAP
reduces productive infection. Equivalent volume of medium
(200 mL) containing virus from 293 T cells transfected with the pNL4-
3 proviral clone (5 mg) and 0.5 mg 3x-Flag-PAP or pcDNA3 vectors was
used to infect 1610
5 MT-2 cells in a 24-well plate. Following 4 hours of
incubation, the cells were washed with fresh medium and incubated for
another 21 days. Aliquots of media were collected every three days and
virus production was determined by p24 CA ELISA. Medium from cells
expressing PAP or vector control is indicated by circles or squares,
respectively. Values are means 6 S.E. from triplicate samples of three
different experiments.
doi:10.1371/journal.pone.0036369.g008
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generate virus particles from cells treated with PD98059 (catalog
# 9900, Cell Signaling), the media of cells were replaced
18 hours following transfection with fresh media containing
PD98059 (20 mM), and media were collected 24 hours later for
virus purification and quantification. The amount of virus in
each sample was determined by p24 CA ELISA (catalog #
BP205, NCI, Frederick, MA) following manufacturer’s instruc-
tions.
Infectivity assays
Single-cycle infectivity assays were performed using 1G5
reporter cells that stably express the luciferase gene downstream
of HIV-1 LTR. Cells were seeded at a density of 1610
5 cells per
well in a 24-well plate immediately prior to infection with HIV-1
virions (12 ng) normalized according to p24 CA amounts.
Infections were performed in the presence of 8 mg/mL polybrene
in five replicates. The cells were washed 3 times with 16 PBS
8 hours following infection and re-suspended in fresh complete
media containing AZT (10 mM) and incubated for an additional
40 hours at 37uC. The cells were harvested and luciferase activity
in cell lysates was measured using a luciferase assay system (catalog
# E4030, Promega) following manufacturer’s recommendations.
MT-2 (1610
5 cells) were infected in 24 well plates with equivalent
amounts of virus (16 ng) or equal volume of media (200 mL)
containing different amounts of virus, in the presence of 8 mg/mL
polybrene. Following a 4-hour incubation, the cells were washed 3
times with 16PBS and cultured in complete media for a period of
21 days. Aliquots of cell supernatants were removed every 3 days
and the amount of virus produced was estimated with p24 CA
ELISA.
Immunoblot analysis
Cells were harvested and lysed in lysis buffer (25 mM HEPES-
KOH pH 7.4, 2 mM EGTA, 1 mM DTT, 10% glycerol, 1%
Nonidet P-40) for 10 minutes on ice. Cells used to show PAP
expression were lysed using nuclear lysis buffer (25 mM HEPES-
KOH pH 7.4, 2 mM EGTA, 1 mM DTT, 10% glycerol, 1%
Nonidet P-40, 1% SDS). Both lysates were thoroughly vortexed
and clarified by centrifugation at 14,0006g for 10 minutes at 4uC
to remove cell debris and proteins were visualized by immunoblot
analysis as described previously [34]. Briefly, 70–150 mg of cell
lysate protein was resolved on a 10–12% SDS-PAGE, transferred
to nitrocellulose and then probed with the indicated antibodies.
Immunoblot analysis of virus particles was performed by dissolving
pelleted virions in 26SDS sample buffer, followed by separation
of viral proteins on a 10–12% SDS-PAGE and probing with the
indicated antibodies.
Virus protein phosphorylation analysis
Equivalent amounts of purified virus particles were pelleted by
centrifugation at 16,0006ga t4 uC for 2 hours. Virus pellets were
then resuspended in 20 mL of reaction buffer (20 mCi of
[c-
33P]ATP, 50 mM HEPES-KOH pH 7.4, 10 mM MgCl2,
0.5% Nonidet P-40), followed by incubation at 30uC for
30 minutes. The reaction was stopped by adding equal volume
of 26 SDS sample buffer and heating at 90uC for 5 minutes.
Samples were then resolved through 12% SDS-PAGE and
visualized using a phosphorimager (BioRad). Equal fractions of
the pelleted virus particles were dissolved in 26SDS sample buffer
and resolved through 12% SDS-PAGE, followed by immunoblot
analysis using anti-p24 CA antibody (1:5,000).
In vitro kinase assays
Cells were harvested 40 hours following transfection and lysed
in lysis buffer (25 mM HEPES-KOH pH 7.4, 2 mM EGTA,
1 mM DTT, 10% glycerol, 1% Nonidet P-40, 1% phosphatase
inhibitor cocktail [Sigma], 16 complete protease inhibitor
cocktail [Roche]). The lysates were cleared by centrifugation at
16,0006 g for 10 minutes at 4uC, following which 300 mgo f
total cellular protein was immunoprecipitated with anti-ERK1/2
antibody (1:1,000) for 4 hours at 4uC with constant agitation.
Protein A Sepharose beads (20 mL) were then added and samples
were agitated for another hour at 4uC, followed by a series of
washes; 25 mM HEPES–KOH pH 7.4 (buffer 1); buffer 1
containing 0.25 M NaCl (buffer 2); buffer 1 containing 0.25 M
NaCl and 1% Triton X-100; then buffer 2 again followed by
buffer 1; culminating with two washes in kinase buffer (20 mM
MOPS pH 7.2, 10 mM MgCl2, 2 mM EGTA, 1 mM DTT,
0.1% Nonidet P-40). An aliquot of the beads was removed and
solubilized in 26 SDS sample buffer, followed by separation
through 12% SDS-PAGE and immunoblot analysis using anti-
ERK1/2 antibody (1:5,000). The remainder of the beads was
used in a kinase assay to measure ERK1/2 activity in cell lysates.
Reactions were performed in a total volume of 20 mL kinase
buffer containing 1.5 mM rATP, 2 mg myelin basic protein
(MBP) as substrate and 10 mCi/mL [c-
33P]ATP. The samples
were incubated at 30uC for 30 minutes and the reaction was
stopped by adding equal volume (20 mL) of 26 SDS sample
buffer. Samples were separated through 12% SDS-PAGE and
phosphorylated proteins were visualized with a phosphorimager
(BioRad).
RNase protection assay
Purified virus particles (equivalent to 150 ng of p24 CA) were
pelleted by centrifugation at 16,0006g for 2 hours at 4uC and total
RNA was isolated using TriReagent (Bioshop) following manufac-
turer’s recommendations. RNA was precipitated with 10 mg tRNA
added to each sample as a carrier. The RNase protection assay was
performed exactly as described previously [8], using a radiolabeled
antisense riboprobe complementary to the gag open reading frame
(ORF) of HIV-1. The probe template was generated by PCR
amplification of nucleotides 600 to 820 of the HXB2 proviral clone
(Accession # K03455.1) using HXB2-600F: 59-CCCCAAGCT-
TAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGC-39
forward and HXB2-820R: 59-CCCCGAATTCTAATACGACT-
CACTATAGGCCCC TTAATACTG -39 reverse primers. The
reverse primer also contained the T7 RNA polymerase promoter
sequence, which was used to transcribe the negative-strand RNA
probe in the presence of 50 mCi of [a-
33P]CTP.
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